Hit It With Your Best Shot- The Case for IO in Early-Stage NSCLC in a Once in a Lifetime World

Editor's Note (June 2026): This episode was recorded prior to Australia's broad PBS listing of nivolumab and ipilimumab, which has removed the previous "once in a lifetime" restriction on immunotherapy. For the latest discussion on these changes and what they mean for lung cancer care, see our recent Conversations in Lung Cancer Research episodes on the broad immunotherapy listing.

---------------

Support TOGA

Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.

---------------

Connect with TOGA

Attend an Event: https://thoraciconcology.org.au/events/

Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/

Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/

Follow Us

LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

X (Twitter): https://x.com/TOGAANZ

Instagram: https://www.instagram.com/togaanz/

YouTube: https://www.youtube.com/@Thoracic_Oncology

---------------

Acknowledgement of Country

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.